MICM
ORIC icon

Matthews International Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Matthews International Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-191,568
Closed -$6.46M – 40
2020
Q2 		$6.46M Buy
+191,568
New +$6.11M 0.5% 25

Other funds holding ORIC

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Matthews International Capital Management's ORIC Position: Q3 2020 in Review

Matthews International Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q3 2020, closing a stake of 191,568 shares — an estimated $6.46M sold.

Matthews International Capital Management first reported a position in ORIC in Q2 2020 and held it in 1 quarter. The position peaked at $6.46M in Q2 2020. 54 funds tracked by Wall St. Rank hold ORIC as of Q3 2020.

  • Matthews International Capital Management reported no remaining Oric Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Matthews International Capital Management sold 191,568 Oric Pharmaceuticals shares in Q3 2020, an estimated $6.46M.
  • Matthews International Capital Management first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Matthews International Capital Management's Oric Pharmaceuticals position peaked at $6.46M in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2020.

Based on Matthews International Capital Management's 13F filing for Q3 2020, filed 5 Nov 2020.